Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Older Patients with Asthma Do Well with Reslizumab | RT
Reslizumab: FDA panel recommends approval for adults, but not children | CHEST Physician
Teva's Asthma Segment: What Could Boost Its Revenues in 2016?
Dosing and Administration
Teva Announces Biologics License Application FDA Acceptance of Reslizumab For Asthma
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
CINQAIR® (reslizumab) Injection – About Asthma Control
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Cinqair (reslizumab): Basics, Side Effects & Reviews
FDA accepts Biological License Application for reslizumab
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Cinqair (reslizumab): Basics, Side Effects & Reviews
Reslizumab Reslizumab (Teva) | Bioz | Ratings For Life-Science Research
Reslizumab Overview - Creative Biolabs
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
CINQAERO (reslizumab) de Teva ya está disponible en España para el asma grave no controlada | IM Farmacias
Israeli Pharma gets FDA Approval for Asthma Antibody
